RCS - LungLife AI, INC - PLA Code application submitted

LungLife AIAnnouncement

12/10/2021 07:05

RNS Number : 7230O
  
LungLife AI, INC
  
12 October 2021
  
 

 
LungLife AI, Inc.

(the "Company" or "LungLife")
 
PLA Code application submitted in first step in reimbursement process
 
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical Association.
 
Reimbursement in the US is comprised of three components: code, price, and coverage. The code is the mechanism by which clinical laboratories can more specifically identify their tests when billing Medicare and commercial insurers. If LungLife's application for a PLA code is granted, the code will be priced for Medicare by the Centers for Medicare & Medicaid Services (CMS) in 2022. PLA code applications can be made at four times in the year.
 
For further information please contact:
 



LungLife AI, Inc.


www.lunglifeai.com




Paul Pagano, CEO 


Via Walbrook PR




David Anderson, CFO


 














Investec Bank plc (Nominated Adviser & Broker)


Tel: +44 (0)20 7597 5970




Daniel Adams / Virginia Bull / Cameron MacRitchie


 








 




Walbrook PR Limited


 Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com




Paul McManus / Alice Woodings


Mob: 07980 541 893 / 07407 804 654



 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRABCBDGBDBDGBB